Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of “Hold” from Analysts

by · The Markets Daily

Insulet Corporation (NASDAQ:PODD – Get Free Report) has been given a consensus recommendation of “Hold” by the twenty-seven research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $195.40.

A number of analysts have weighed in on the company. Robert W. Baird set a $175.00 price target on Insulet in a research report on Thursday, August 6th. Canaccord Genuity Group dropped their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Benchmark lowered their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings lowered shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. Finally, Truist Financial restated a “hold” rating and set a $153.00 price target (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th.

Check Out Our Latest Stock Report on PODD

Insulet Stock Performance

Shares of NASDAQ PODD opened at $131.96 on Friday. The business’s 50-day moving average price is $152.36 and its two-hundred day moving average price is $173.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet has a one year low of $126.40 and a one year high of $354.88. The company has a market capitalization of $9.15 billion, a P/E ratio of 24.67, a price-to-earnings-growth ratio of 1.06 and a beta of 1.08.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts anticipate that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC raised its stake in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares during the last quarter. Cresset Asset Management LLC lifted its stake in shares of Insulet by 7.3% in the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after buying an additional 177 shares during the period. Cerity Partners LLC lifted its stake in shares of Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after buying an additional 7,030 shares during the period. Sei Investments Co. grew its position in Insulet by 27.4% during the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after buying an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its stake in Insulet by 2.5% during the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after acquiring an additional 791 shares during the period.

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

Recommended Stories